Skip to main content

Surrozen, Inc.

corporate_fare Company Profile

Surrozen, Inc.

SRZN·NASDAQ·Life Sciences·CIK 0001824893

We are a biotechnology company focused on discovering and developing product candidates that selectively adjust the Wnt pathway, which is crucial for tissue repair. Our primary focus is ophthalmology, where Wnt signaling is vital for retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California. Our goal is to revolutionize the treatment of serious eye diseases by fully utilizing the Wnt pathway. Based on the foundational work of our founders and scientific advisors who identified the Wnt gene and its key regulators, we have made significant discoveries. These discoveries allow us to rapidly and flexibly create tissue-targeted treatments that modulate Wnt signaling, forming the basis of our ophthalmology portfolio and research programs. These programs aim to restore tissue structure and function in serious eye diseases with significant unmet medical needs. Our main product candidates are multi-specific, antibody-based treatments that imitate natural Wnt proteins, which activate and enhance the Wnt pathway. Wnt signaling is essential for tissue maintenance and regeneration throughout the body. Our current development efforts are concentrated on ophthalmology because the Wnt pathway's biology is clinically proven in this area, and localized delivery allows for controlled therapeutic modulation. Our strategy involves identifying diseases responsive to Wnt modulation, designing tissue-selective treatments, evaluating mechanisms that complement Wnt signaling, and advancing candidates into clinical development for specific ophthalmic conditions with high unmet need. Our approach and platform technologies have led to the discovery and advancement of multiple product candidates. We believe ophthalmology indications are particularly suitable for Wnt modulating therapeutics due to strong genetic and biological validation and the need for methods to restore tissue structure and function.

Surrozen, Inc. (NASDAQ:SRZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for SRZN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for SRZN spans 10-Q, 8-K, SCHEDULE 13D/A, 424B5.

Recent high-impact activity:

  • Surrozen Raises $60M in Stock Sale at 1.2% Discount to Thursday's Close
  • Surrozen Q3: $129.7M Non-Cash Loss, Boehringer Arbitration Disclosed, Cash Into 2029
  • Surrozen Q3: DUET Phase 2a Expanded to 150 Patients, Cash Runway Into 2029
  • Surrozen Posts $129.7M Q3 Net Loss as Operating Expenses Hit $17.6M
  • Surrozen Closes $95.1M Final Tranche, Extends Cash Runway Into 2029

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.48M
Net Income
-$242.03M
Diluted EPS
-$32.37
Op. Cash Flow
-$30.24M
Free Cash Flow
-$30.37M
Operating Income
-$42.09M
Cash & Equivalents
$89.25M
Debt / Equity
0.00×
Net Margin
-69.61×
Shares Outstanding
9.78M sh
Source: 10-K · filed 2026-03-23 · accession 0001193125-26-119818

Short Interest & Short Volume

8.51 days to cover

FINRA reported short interest of 3,234,984 shares in SRZN as of the October 30, 2026 settlement, a 3.3% increase from the prior period — about 8.5 days to cover at its recent average daily volume. On November 20, 2026, 52.7% of SRZN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,234,984 shares as of October 30, 2026
Change vs prior period▲ 3.3%
Days to cover8.51 at avg daily volume of 379,990
Daily short volume (FINRA facilities)52.7% of 53,983 shares on November 20, 2026
5-day average short volume43.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for SRZN, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.

1 recent capital raise1 shelf registration

Offering Terms Unchanged From Pricing · Net Proceeds and Fees

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$31.5 +2.71% today
52-week range · as of 2026-11-09 $11.51 – $37.83
Market cap
$542.49M
Volume
148.8K (0.4× avg)
3-mo avg 343.2K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SRZN - Latest Insights

SRZN
Nov 13, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $32.05
Real-time Price: $31.50 info
Change: -$0.550 (-2%) info
Market Cap: $542.495M info
SRZN
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.50 info
Change: -$0.500 (-2%) info
Market Cap: $542.495M info
SRZN
Nov 09, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.50 info
Change: -$0.500 (-2%) info
Market Cap: $542.495M info
SRZN
Nov 09, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $31.50 info
Change: -$0.500 (-2%) info
Market Cap: $542.495M info
SRZN
Oct 20, 2026, 4:59 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $25.14
Real-time Price: $31.50 info
Change: +$6.36 (+25%) info
Market Cap: $542.495M info
SRZN
Oct 02, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.13
Real-time Price: $31.50 info
Change: +$1.37 (+5%) info
Market Cap: $542.495M info
SRZN
Oct 02, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.13
Real-time Price: $31.50 info
Change: +$1.37 (+5%) info
Market Cap: $542.495M info
SRZN
Sep 24, 2026, 11:41 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $31.51
Real-time Price: $31.50 info
Change: -$0.010 (-0.03%) info
Market Cap: $542.495M info
SRZN
May 18, 2026, 6:49 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $28.15
Real-time Price: $31.50 info
Change: +$3.35 (+12%) info
Market Cap: $542.495M info
SRZN
May 06, 2026, 4:49 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $34.13
Real-time Price: $31.50 info
Change: -$2.63 (-8%) info
Market Cap: $542.495M info
SRZN
May 06, 2026, 4:38 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $34.13
Real-time Price: $31.50 info
Change: -$2.63 (-8%) info
Market Cap: $542.495M info
SRZN
Mar 30, 2026, 6:21 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $27.45
Real-time Price: $31.50 info
Change: +$4.05 (+15%) info
Market Cap: $542.495M info
SRZN
Mar 25, 2026, 8:02 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $26.14
Real-time Price: $31.50 info
Change: +$5.36 (+21%) info
Market Cap: $542.495M info
SRZN
Mar 23, 2026, 5:26 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $25.24
Real-time Price: $31.50 info
Change: +$6.26 (+25%) info
Market Cap: $542.495M info
SRZN
Mar 23, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $25.24
Real-time Price: $31.50 info
Change: +$6.26 (+25%) info
Market Cap: $542.495M info
SRZN
Mar 23, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.24
Real-time Price: $31.50 info
Change: +$6.26 (+25%) info
Market Cap: $542.495M info
SRZN
Mar 23, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $25.24
Real-time Price: $31.50 info
Change: +$6.26 (+25%) info
Market Cap: $542.495M info
SRZN
Mar 16, 2026, 7:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $25.50
Real-time Price: $31.50 info
Change: +$6.00 (+24%) info
Market Cap: $542.495M info
SRZN
Jan 22, 2026, 6:55 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $20.25
Real-time Price: $31.50 info
Change: +$11.25 (+56%) info
Market Cap: $542.495M info
SRZN
Jan 20, 2026, 7:35 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $18.26
Real-time Price: $31.50 info
Change: +$13.24 (+73%) info
Market Cap: $542.495M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets